Search results for "From ACP Journal Club"
Intensive weight management in primary care improved weight loss and remission of type 2 diabetes
The author of an ACP Journal Club commentary said that the intervention effect was strong enough to prompt a reconsideration of primary care management of obesity and that the results of the trial may motivate patients to lose enough weight to reverse diabetes.
https://diabetes.acponline.org/archives/2018/04/13/8.htm
13 Apr 2018
Review: Evidence is inconclusive on metabolic surgery vs. medical treatment for microvascular complications in T2DM
A meta-analysis from earlier this year that compared the effects of metabolic surgery and medical treatment found 10 studies to include, only three of them randomized controlled trials.
https://diabetes.acponline.org/archives/2018/08/10/7.htm
10 Aug 2018
Studies show benefits of glucagon-like peptide-1 receptor agonists
A commentary reviewed the findings of REWIND, PIONEER 6, and PIONEER 4 trials, which studied the cardiovascular and glycemic control effects of dulaglutide, semaglutide, and liraglutide.
https://diabetes.acponline.org/archives/2019/10/11/7.htm
11 Oct 2019
Two reviews analyze efficacy of newer drug classes in type 1 and type 2 diabetes
The evidence favors glucagon-like peptide 1 agonists and, particularly, sodium–glucose cotransporter 2 inhibitors for type 2 diabetes, but the benefits in type 1 diabetes remain speculative, said an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2018/08/10/8.htm
10 Aug 2018
Review: In type 2 diabetes, adding dipeptidyl peptidase-4 inhibitors to sulfonylureas increases hypoglycemia
Adding dipeptidyl peptidase-4 (DPP-4) inhibitors to sulfonylureas was associated with 1 excess case of hypoglycemia for every 17 patients in the first 6 months of treatment, the systematic review and meta-analysis found.
https://diabetes.acponline.org/archives/2016/09/16/5.htm
16 Sep 2016
In men who are overweight or obese, adding testosterone therapy reduced glucose intolerance/T2DM
A industry-funded trial found improved glucose control in men randomized to testosterone injections, but some of its claims were exaggerated, and routine use of testosterone therapy to prevent or reverse type 2 diabetes is not recommended, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/05/14/7.htm
14 May 2021
In high-risk T2DM, canagliflozin reduced CV events regardless of baseline renal function
The results of the CANVAS trial are promising for patients with type 2 diabetes mellitus (T2DM) and early chronic kidney disease, but ongoing research should provide more convincing data, said an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2019/03/08/6.htm
8 Mar 2019
In type 2 diabetes, weekly semaglutide reduced HbA1c and increased weight loss more than weekly exenatide ER
Exenatide is still an effective alternative for patients who cannot tolerate semaglutide due to gastrointestinal adverse events, noted the ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2018/05/11/7.htm
11 May 2018
Review: Viscous fiber reduces HbA1c, fasting glucose, and insulin resistance in type 2 diabetes
An ACP Journal Club commentary recommends advising patients with type 2 diabetes who don't smoke and who take metformin to also consider increasing their soluble fiber intake by more than 10 g/d.
https://diabetes.acponline.org/archives/2019/06/14/6.htm
14 Jun 2019
In high-risk T1DM, real-time continuous glucose monitoring vs self-monitoring reduced hypoglycemic events
The study provides compelling evidence for clinicians to recommend real-time continuous glucose monitoring to their patients at high risk for severe hypoglycemia, the ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2018/06/08/7.htm
8 Jun 2018